Replies to post #131214 on Biotech Values

[biomaven0]

I'm of the opinion when a stock is hot and has a lot of $$$ built into it's stock price on "success" of a trial or potential approval of a drug they should always raise some cash as a hedge.

Normally I would agree with you, but ponatinib is as much a lock for approval as any drug I've ever followed in my 15 years of biotech investing. I'm not saying it's a lock for 1st line treatment or even 2nd line, but for 3rd line it's a lock.

I predict that they will partner in Asia and maybe ROW. How much they get upfront will drive the need for another offering. I personally don't think any offering is coming in the near term. He did say at Lazard they want to "retain the global rights" to ponatinib, and were going to commercialize it in the US and Europe. I'm assuming that language leaves open the possibility of a marketing partner in ROW.

Peter